Genomic Vision

Genomic Vision Equity

The The Equity of Genomic Vision (GV.PA) as of Oct 22, 2026 is -1.29 M EUR. In the previous year, The Equity was 3.07 M EUR — a change of -141.99% (lower).

Equity

-1.29 MEUR

YoY

-141.99%

Last updated:

In 2022, Genomic Vision's equity was -1.29 M EUR, a -141.99% increase from the 3.07 M EUR equity in the previous year.

The Genomic Vision Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
18.38 M EUR
Jan 1, 2016
10.04 M EUR
Jan 1, 2017
3.76 M EUR
Jan 1, 2018
4.17 M EUR
Jan 1, 2019
3.23 M EUR
Jan 1, 2020
3.12 M EUR
Jan 1, 2021
3.07 M EUR
Jan 1, 2022
-1.29 M EUR
The Genomic Vision Equity history
YEAREquityYoY
-1.29 MEUR-141.99%
3.07 MEUR-1.70%
3.12 MEUR-3.22%
3.23 MEUR-22.56%
4.17 MEUR+10.91%
3.76 MEUR-62.56%
10.04 MEUR-45.40%
18.38 MEUR-19.03%
22.70 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Genomic Vision's Equity

Genomic Vision's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Genomic Vision's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Genomic Vision's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Genomic Vision's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Genomic Vision’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Genomic Vision stock

The Equity of Genomic Vision is -1.29 M EUR in 2022.

The Equity of Genomic Vision changed from 3.07 M EUR to -1.29 M EUR, representing a -141.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Genomic Vision historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Genomic Vision

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genomic Vision